The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

The field of immunogerontology investigates age-associated declines in immune function, particularly focusing on the reduced lymphoid potential of ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

The illustration depicts how during differentiation cells normally lose their plasticity and ability to acquire new fates.

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...